Liquid biopsy in ovarian cancer
- PMID: 32448432
- DOI: 10.1016/bs.acc.2020.01.001
Liquid biopsy in ovarian cancer
Abstract
Ovarian cancer has the worst survival rate because it is typically diagnosed at advanced stage. Despite treatment, the disease commonly recurs due to chemo-resistance. Liquid biopsy, based on minimally invasive blood tests, has the advantage of following tumor evolution in real time, offering novel insights on cancer prevention and treatment. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating cell-free microRNAs (cfmiRNAs) and circulating exosomes represent the major components of liquid biopsy. In this chapter, we provide an overview of recent research on CTCs, ctDNA, cfmiRNAs and exosomes in ovarian cancer. We also focus on the clinical value of liquid biopsy in early diagnosis, prognosis, treatment response, as well as screening in the general population.
Keywords: Circulating miRNAs; Circulating tumor DNA; Circulating tumor cells; Exosomes; Liquid biopsy; Ovarian cancer.
© 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest All authors have read the policy on disclosure of potential conflicts of interest. The authors have declared no conflicts of interest.
Similar articles
-
Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.Transl Res. 2019 Mar;205:77-91. doi: 10.1016/j.trsl.2018.10.003. Epub 2018 Oct 12. Transl Res. 2019. PMID: 30391474 Review.
-
Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.Clin Chem Lab Med. 2018 Jan 26;56(2):186-197. doi: 10.1515/cclm-2017-0019. Clin Chem Lab Med. 2018. PMID: 28753534 Review.
-
Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?Cancer Lett. 2020 Jan 1;468:59-71. doi: 10.1016/j.canlet.2019.10.014. Epub 2019 Oct 11. Cancer Lett. 2020. PMID: 31610267 Review.
-
Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.Clin Chim Acta. 2019 Aug;495:331-337. doi: 10.1016/j.cca.2019.04.082. Epub 2019 May 2. Clin Chim Acta. 2019. PMID: 31054913 Review.
-
The potential of liquid biopsy in the management of cancer patients.Semin Cancer Biol. 2022 Sep;84:69-79. doi: 10.1016/j.semcancer.2022.03.013. Epub 2022 Mar 21. Semin Cancer Biol. 2022. PMID: 35331850 Review.
Cited by
-
Profiling the metabolome of uterine fluid for early detection of ovarian cancer.Cell Rep Med. 2023 Jun 20;4(6):101061. doi: 10.1016/j.xcrm.2023.101061. Epub 2023 Jun 1. Cell Rep Med. 2023. PMID: 37267943 Free PMC article.
-
Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients.Cancers (Basel). 2022 Aug 4;14(15):3790. doi: 10.3390/cancers14153790. Cancers (Basel). 2022. PMID: 35954453 Free PMC article.
-
Extracellular MicroRNAs as Intercellular Mediators and Noninvasive Biomarkers of Cancer.Cancers (Basel). 2020 Nov 20;12(11):3455. doi: 10.3390/cancers12113455. Cancers (Basel). 2020. PMID: 33233600 Free PMC article. Review.
-
Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer.Exp Ther Med. 2022 Jun 30;24(3):542. doi: 10.3892/etm.2022.11479. eCollection 2022 Sep. Exp Ther Med. 2022. PMID: 35978934 Free PMC article.
-
Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer.Transl Cancer Res. 2022 Aug;11(8):2636-2646. doi: 10.21037/tcr-22-529. Transl Cancer Res. 2022. PMID: 36093536 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
